An interventional study of HistoSonics System in Liver Neoplasms, Hepatocellular Carcinoma and Liver Metastases, sponsored by HistoSonics, Inc.. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by HistoSonics, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.
Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 109th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2021, is one of 15 with no phase, reaches primary completion later than 2 of the 37 other live ones, and was the 110th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:
AIO-Studien-gGmbH · Sites in Germany
Ages 18+
RWTH Aachen University · Sites in Germany
Ages 18–80
CatalYm GmbH · Sites in Germany, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Germany, United States, Australia and 11 more countries
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 59 · Phase 3 37 · Phase 4 4
First in 1999; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 128 across the 124 interventional studies, 250 across the 25 observational. Of the 101 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 149 have an industry lead sponsor. The 10 most frequent:
HistoSonics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
HistoSonics, Inc. has 4 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
11 of the studies in Carcinoma, Hepatocellular with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05911633Terumo Europe N.V.BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | 2026-11-30 |
| NCT05844046Enrico De ToniSequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients | 2026-12-31 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
This trial is a single arm, non-randomized, multicenter, prospective trial. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Subjects will then be followed for 30 days. Additionally, subjects will be evaluated at 6 months and followed annually for up to five (5) years post-index procedure.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
This study's enrollment of 24 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →HistoSonics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is diagnosed with hepatocellular carcinoma (HCC) or liver (mets) from other primary cancers
Subject meets the following functional criteria, ≤7 days prior to the planned index-procedure date:
Note: If the subject is treated with surgical resection prior to the index procedure, the resection must be performed ≥2 weeks prior to the planned index-procedure date
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: HistoSonics System
The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
Also known as: Histotripsy
Primary Efficacy: Technical Success
Technical success, defined as the treatment volume/treatment dimensions being greater than or equal to the targeted tumor, and with complete tumor coverage, via computed tomography (CT) or magnetic resonance (MR) imaging. \[Core Laboratory Adjudicated\]
Time frame: ≤36 hours post-index procedure
Primary Safety: Procedure-Related Major Complications
Number of index procedure related major complications, including device-related events defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher toxicities observed up to 30-days post index-procedure. \[Clinical Events Committee Adjudicated\]
Time frame: 30 days post-index procedure
Secondary Efficacy: Technique Efficacy
Technique efficacy, defined as the lack of a nodular or mass-like area of enhancement within or along the edge of the treatment volume assessed via CT or MR imaging at 30-days post-procedure. \[Core Laboratory Adjudicated\]
Time frame: 30 days post-index procedure
Secondary Safety: All Adverse Events
Number of adverse events (serious and non-serious) reported within 30 days post-index procedure. \[Clinical Events Committee Adjudicated\]
Time frame: 30 days post-index procedure
The trial was designed to enroll up to 45 participants; however, enrollment was stopped after 24 participants were enrolled due to completion of the primary analysis of #HOPE4LIVER US (NCT04572633). The primary analysis assessed the primary and secondary endpoints at 30 days using pooled data from #HOPE4LIVER EU/UK and #HOPE4LIVER US after a total of 40 evaluable participants enrolled between the two trials. Follow-up beyond 30 days is ongoing.
| Milestone | HistoSonics System |
|---|---|
| Started | 24 |
| Completed | 0 |
| Not completed | 24 |
| Withdrew: Participant in active follow-up at 30 days | 24 |
Technical success, defined as the treatment volume/treatment dimensions being greater than or equal to the targeted tumor, and with complete tumor coverage, via computed tomography (CT) or magnetic resonance (MR) imaging. \[Core Laboratory Adjudicated\]
| percentage of tumors | HistoSonics System |
|---|---|
| Primary Efficacy: Technical Success | 100 (100 to 100) |
Number of index procedure related major complications, including device-related events defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher toxicities observed up to 30-days post index-procedure. \[Clinical Events Committee Adjudicated\]
| percentage of participants | HistoSonics System |
|---|---|
| Primary Safety: Procedure-Related Major Complications | 12.5 (4.3 to 31.0) |
Technique efficacy, defined as the lack of a nodular or mass-like area of enhancement within or along the edge of the treatment volume assessed via CT or MR imaging at 30-days post-procedure. \[Core Laboratory Adjudicated\]
| percentage of tumors | HistoSonics System |
|---|---|
| Secondary Efficacy: Technique Efficacy | 100 (100 to 100) |
Number of adverse events (serious and non-serious) reported within 30 days post-index procedure. \[Clinical Events Committee Adjudicated\]
| adverse events | HistoSonics System |
|---|---|
| Secondary Safety: All Adverse Events | 38 |
Collected over Enrollment through 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HistoSonics System | 0/24 (0%) | 7/24 (29.2%) | 14/24 (58.3%) |
| Event | HistoSonics System |
|---|---|
| Hepatic failureHepatobiliary disorders | 1/24 |
| Postoperative thrombosisInjury, poisoning and procedural complications | 1/24 |
| Procedural painInjury, poisoning and procedural complications | 1/24 |
| Splenic haematomaBlood and lymphatic system disorders | 1/24 |
| Melaena/MelenaGastrointestinal disorders | 1/24 |
| Chest painGeneral disorders | 1/24 |
| SepsisInfections and infestations | 1/24 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 1/24 |
| Event | HistoSonics System |
|---|---|
| Procedural painInjury, poisoning and procedural complications | 6/24 |
| PyrexiaGeneral disorders | 4/24 |
| Abdominal painGastrointestinal disorders | 3/24 |
| Anaemia/AnemiaBlood and lymphatic system disorders | 2/24 |
| Abdominal pain upperGastrointestinal disorders | 1/24 |
| ConstipationGastrointestinal disorders | 1/24 |
| AstheniaGeneral disorders | 1/24 |
| DiscomfortGeneral disorders | 1/24 |
| Localized oedemaGeneral disorders | 1/24 |
| Procedural nauseaInjury, poisoning and procedural complications | 1/24 |
| Age, Continuous(years) | HistoSonics System |
|---|---|
| Mean | 62.9 ± 10.0 |
| Sex: Female, Male(Participants) | HistoSonics System |
|---|---|
| Female | 14 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | HistoSonics System |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | HistoSonics System |
|---|---|
| White | 23 |
| Other | 1 |
| Type of tumor(Participants) | HistoSonics System |
|---|---|
| Hepatocellular carcinoma | 7 |
| Liver metastasis | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Sep 2022, 15 months.
Results were first posted in Aug 2024, 1 year 10 months after primary completion.
Of 385 interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 75. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HistoSonics, Inc.